Skip to main content
. Author manuscript; available in PMC: 2021 Apr 28.
Published in final edited form as: J Am Coll Cardiol. 2020 Apr 28;75(16):1956–1974. doi: 10.1016/j.jacc.2020.02.056

FIGURE 2. Selecting Pharmacologic Therapy for Patients With Type 2 Diabetes.

FIGURE 2

The evidence base for selecting pharmacologic therapy for patients with type 2 diabetes depends on presence of risk factors, comorbid heart failure, atherosclerotic disease, and renal disease. ASCVD = atherosclerotic cardiovascular disease; CKD = chronic kidney disease; CVD = cardiovascular disease; CVOT = cardiovascular outcome trial; DDP4i = dipeptidyl peptidase 4 inhibitor; HF = heart failure; RF = ■■■; TZD = ■■■; other abbreviations as in Figure 1.